GGHC
INSY

Gilder Gagnon Howe & Co’s Insys Therapeutics, Inc. INSY Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-33,244
Closed -$689K – 326
2014
Q1 		$689K Buy
+33,244
New +$659K 0.01% 220

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
BTP
Bloom Tree Partners New York $215M AUM 17.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Gilder Gagnon Howe & Co's INSY Position: Q2 2014 in Review

Gilder Gagnon Howe & Co sold out of Insys Therapeutics, Inc. (INSY) in Q2 2014, closing a stake of 33,244 shares — an estimated $689K sold.

Gilder Gagnon Howe & Co first reported a position in INSY in Q1 2014 and held it in 1 quarter. The position peaked at $689K in Q1 2014. 99 funds tracked by Wall St. Rank hold INSY as of Q2 2014.

  • Gilder Gagnon Howe & Co reported no remaining Insys Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 33,244 Insys Therapeutics, Inc. shares in Q2 2014, an estimated $689K.
  • Gilder Gagnon Howe & Co first reported a position in Insys Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Insys Therapeutics, Inc. position peaked at $689K in Q1 2014.
  • 99 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2014.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2014, filed 1 Aug 2014.